First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors

10.1371/journal.pone.0083232

Saved in:

Bibliographic Details
Main Authors:	Mross K., Richly H., Fischer R., Scharr D., Büchert M., Stern A., Gille H., Audoly L.P., Scheulen M.E.
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2019
Subjects:	angiocal bilirubin gamma glutamyltransferase gelatinase A prs 050 unclassified drug uric acid vasculotropin A vasculotropin inhibitor angiocal protein angiogenesis inhibitor lipocalin lipocalin 1 MMP2 protein, human VEGFA protein, human abdominal pain adult advanced cancer aged area under the curve article backache bilirubin blood level body weight disorder cancer pain cancer surgery chill clinical article colorectal carcinoma constipation decreased appetite dose response drug clearance drug distribution drug dose escalation drug exposure drug half life drug protein binding drug safety drug tolerability dyspepsia dyspnea fatigue female fever flatulence gamma glutamyl transferase blood level human hypertension hypotension liver cell carcinoma male maximum plasma concentration melanoma nausea neuroendocrine tumor open study pancreas carcinoma peripheral edema pharmacodynamics phase 1 clinical trial plasma concentration-time curve recommended drug dose repeated drug dose rigor single drug dose small intestine perforation solid tumor systemic therapy unspecified side effect uric acid blood level weight reduction antagonists and inhibitors blood clinical trial middle aged Neoplasms time Adult Aged Angiogenesis Inhibitors Dose-Response Relationship, Drug Female Humans Lipocalin 1 Lipocalins Matrix Metalloproteinase 2 Middle Aged Time Factors Vascular Endothelial Growth Factor A
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/161444
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-161444
record_format	dspace
spelling	sg-nus-scholar.10635-1614442023-10-31T20:36:37Z First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors Mross K. Richly H. Fischer R. Scharr D. Büchert M. Stern A. Gille H. Audoly L.P. Scheulen M.E. DUKE-NUS MEDICAL SCHOOL angiocal bilirubin gamma glutamyltransferase gelatinase A prs 050 unclassified drug uric acid vasculotropin A vasculotropin inhibitor angiocal protein angiogenesis inhibitor gelatinase A lipocalin lipocalin 1 MMP2 protein, human vasculotropin A VEGFA protein, human abdominal pain adult advanced cancer aged area under the curve article backache bilirubin blood level body weight disorder cancer pain cancer surgery chill clinical article colorectal carcinoma constipation decreased appetite dose response drug clearance drug distribution drug dose escalation drug exposure drug half life drug protein binding drug safety drug tolerability dyspepsia dyspnea fatigue female fever flatulence gamma glutamyl transferase blood level human hypertension hypotension liver cell carcinoma male maximum plasma concentration melanoma nausea neuroendocrine tumor open study pancreas carcinoma peripheral edema pharmacodynamics phase 1 clinical trial plasma concentration-time curve recommended drug dose repeated drug dose rigor single drug dose small intestine perforation solid tumor systemic therapy unspecified side effect uric acid blood level weight reduction antagonists and inhibitors blood clinical trial middle aged Neoplasms time Adult Aged Angiogenesis Inhibitors Dose-Response Relationship, Drug Female Humans Lipocalin 1 Lipocalins Matrix Metalloproteinase 2 Middle Aged Neoplasms Time Factors Vascular Endothelial Growth Factor A 10.1371/journal.pone.0083232 PLoS ONE 8 12 e83232 2019-11-05T02:06:55Z 2019-11-05T02:06:55Z 2013 Article Mross K., Richly H., Fischer R., Scharr D., Büchert M., Stern A., Gille H., Audoly L.P., Scheulen M.E. (2013). First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS ONE 8 (12) : e83232. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0083232 1932-6203 https://scholarbank.nus.edu.sg/handle/10635/161444 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20191101
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	angiocal bilirubin gamma glutamyltransferase gelatinase A prs 050 unclassified drug uric acid vasculotropin A vasculotropin inhibitor angiocal protein angiogenesis inhibitor gelatinase A lipocalin lipocalin 1 MMP2 protein, human vasculotropin A VEGFA protein, human abdominal pain adult advanced cancer aged area under the curve article backache bilirubin blood level body weight disorder cancer pain cancer surgery chill clinical article colorectal carcinoma constipation decreased appetite dose response drug clearance drug distribution drug dose escalation drug exposure drug half life drug protein binding drug safety drug tolerability dyspepsia dyspnea fatigue female fever flatulence gamma glutamyl transferase blood level human hypertension hypotension liver cell carcinoma male maximum plasma concentration melanoma nausea neuroendocrine tumor open study pancreas carcinoma peripheral edema pharmacodynamics phase 1 clinical trial plasma concentration-time curve recommended drug dose repeated drug dose rigor single drug dose small intestine perforation solid tumor systemic therapy unspecified side effect uric acid blood level weight reduction antagonists and inhibitors blood clinical trial middle aged Neoplasms time Adult Aged Angiogenesis Inhibitors Dose-Response Relationship, Drug Female Humans Lipocalin 1 Lipocalins Matrix Metalloproteinase 2 Middle Aged Neoplasms Time Factors Vascular Endothelial Growth Factor A
spellingShingle	angiocal bilirubin gamma glutamyltransferase gelatinase A prs 050 unclassified drug uric acid vasculotropin A vasculotropin inhibitor angiocal protein angiogenesis inhibitor gelatinase A lipocalin lipocalin 1 MMP2 protein, human vasculotropin A VEGFA protein, human abdominal pain adult advanced cancer aged area under the curve article backache bilirubin blood level body weight disorder cancer pain cancer surgery chill clinical article colorectal carcinoma constipation decreased appetite dose response drug clearance drug distribution drug dose escalation drug exposure drug half life drug protein binding drug safety drug tolerability dyspepsia dyspnea fatigue female fever flatulence gamma glutamyl transferase blood level human hypertension hypotension liver cell carcinoma male maximum plasma concentration melanoma nausea neuroendocrine tumor open study pancreas carcinoma peripheral edema pharmacodynamics phase 1 clinical trial plasma concentration-time curve recommended drug dose repeated drug dose rigor single drug dose small intestine perforation solid tumor systemic therapy unspecified side effect uric acid blood level weight reduction antagonists and inhibitors blood clinical trial middle aged Neoplasms time Adult Aged Angiogenesis Inhibitors Dose-Response Relationship, Drug Female Humans Lipocalin 1 Lipocalins Matrix Metalloproteinase 2 Middle Aged Neoplasms Time Factors Vascular Endothelial Growth Factor A Mross K. Richly H. Fischer R. Scharr D. Büchert M. Stern A. Gille H. Audoly L.P. Scheulen M.E. First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
description	10.1371/journal.pone.0083232
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Mross K. Richly H. Fischer R. Scharr D. Büchert M. Stern A. Gille H. Audoly L.P. Scheulen M.E.
format	Article
author	Mross K. Richly H. Fischer R. Scharr D. Büchert M. Stern A. Gille H. Audoly L.P. Scheulen M.E.
author_sort	Mross K.
title	First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
title_short	First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
title_full	First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
title_fullStr	First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
title_full_unstemmed	First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
title_sort	first-in-human phase i study of prs-050 (angiocal), an anticalin targeting and antagonizing vegf-a, in patients with advanced solid tumors
publishDate	2019
url	https://scholarbank.nus.edu.sg/handle/10635/161444
_version_	1781791764122697728

First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors

Similar Items